Category - Developments

Developments

POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center

POINT Biopharma Global (NASDAQ:PNT) entered into a technology license agreement with the Belgian Nuclear Research Center (SCK CEN) for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added...

November 24, 2021

Developments

111, Inc. Q3 net revenue climbs 41.6% to RMB 3.35 billion

111, Inc. (NASDAQ:YI), a leading tech-enabled healthcare platform in China, reported that third quarter net revenue rose 41.6% to RMB3.35 billion, or $519.3-milion (U.S.). In a statement, Junling Liu, co-founder...

November 19, 2021

Developments

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Oravax Medical, a unit of Oramed Pharmaceuticals (NASDAQ, TASE:ORMP), and Genomma Lab Internacional (BMV:LABB) formed of a 50/50 joint venture to develop and commercialize Oravax’s oral COVID-19 vaccine candidate...

November 18, 2021

Developments

Hepion, FibroFind report positive anti-cancer activity of CRV431 in liver cancer study

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. In addition...

November 16, 2021

Developments

Posters on use of Altamira’s RNA delivery platforms presented at AHA scientific sessions

Altamira Therapeutics (NASDAQ:CYTO) announced the presentation of data at the American Heart Association scientific sessions from two studies by a research group at Washington University, St. Louis, on the use of the...

November 15, 2021

Developments

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for...

November 12, 2021

Developments

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Results from a study conducted by Dr. Philippe Gallay’s research group at The Scripps Research Institute examining the anti-tumor mechanism of Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate, CRV431, will be...

November 10, 2021

Developments

Cognetivity Neurosciences presents new results at AD conference

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF; FWB:1UB) presented significant new results demonstrating the capabilities of its Integrated Cognitive Assessment (ICA) platform at the Clinical Trials on Alzheimer’s...

November 9, 2021

Developments

Soricimed, Mount Allison University to collaborate on novel biopesticide solution

Closely-held Soricimed Biopharma and Dr. Vett Lloyd, a professor in the Biology Department at Mount Allison University and head of the Lloyd Tick Lab, are collaborating to design a species-specific, microbial...

November 9, 2021

Developments

BerGenBio presents bemcentinib data in NSCLC; receives FDA fast track

BerGenBio ASA (OSE:BGBIO) will deliver an e-poster presentation at the online Society for Immunotherapy of Cancer meeting with preclinical and clinical data suggesting that bemcentinib restored response to anti-PD-1...

November 9, 2021

Category - Developments

POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center

111, Inc. Q3 net revenue climbs 41.6% to RMB 3.35 billion

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Hepion, FibroFind report positive anti-cancer activity of CRV431 in liver cancer study

Posters on use of Altamira’s RNA delivery platforms presented at AHA scientific sessions

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Cognetivity Neurosciences presents new results at AD conference

Soricimed, Mount Allison University to collaborate on novel biopesticide solution

BerGenBio presents bemcentinib data in NSCLC; receives FDA fast track

General

More